Gynecologic Cancers
Secondline Maintenance PARP Inhibition in Ovarian Cancer: Pros and Cons
January 02, 2021
Article
“Second-line maintenance therapy is going to be incredibly important for patients because we know that once a patient with ovarian cancer recurs, their disease is incurable,” said Puechl. “Second-line maintenance therapy should be considered for these patients because it can [provide] meaningful time that is largely free of [chemotherapy-related] toxicities.”
Immunotherapy in Gynecologic Cancers Shows Progress but Has a Long Way to Go
November 07, 2020
Article
Ursula Matulonis, MD, highlights immunotherapy agents have demonstrated moderate clinical activity for patients with gynecologic cancers, however they fail to yield significant response rates in both the newly-diagnosed and recurrent settings.
PARP Inhibitor Resistance in Ovarian Cancer: We Need More Trials
November 03, 2020
Article
While PARP inhibitors have played a large part in improving progression-free survival (PFS) in patients with ovarian cancer, long-term use of these agents often leads to resistance that are often quite challenging to overcome, according to Gottfried E. Konecny, MD.
FDA Approves Biomarker Test for High-Risk HPV-Related Cervical Cancer Risk
September 16, 2020
Article
The FDA approved the CINtec PLUS Cytology test to help determine if HPV-positive women need further diagnostic procedures to prevent cervical cancer.
Cervical Cancer: Symptoms, Treatments, and Outlooks
August 05, 2020
Article
Cervical cancer is often diagnosed in the later stages, though incidence of the disease is declining thanks to the HPV vaccine.
Pap, HPV Testing Decreases Cancer Risk, But Testing Timeline Is Still Debated
July 14, 2020
Article
Pap and HPV testing can decrease cervical cancer risk, but testing intervals seem to be sporadic for patients.
Pembrolizumab Shows Modest Activity in Advanced Ovarian, Gynecologic Cancers
June 24, 2020
Article
Pembrolizumab (Keytruda) demonstrated modest clinical activity in patients with advanced recurrent ovarian cancer, according to final results of the phase 2 KEYNOTE-100 trial that were presented during the 2020 ASCO Virtual Scientific Program.
FDA Approves Olaparib Plus Bevacizumab for Frontline Maintenance Treatment of HRD+ Ovarian Cancer
May 08, 2020
Article
The FDA has approved the combination of olaparib (Lynparza) and bevacizumab (Avastin) for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response (PR) to first-line platinum-based chemotherapy with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)–positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.
Vaccine Promising in Cervical Cancer
May 08, 2020
Article
The vaccine BVAC-C demonstrated durable antitumor activity in patients with HPV 16– or HPV 18–positive recurrent cervical cancer, according to findings presented at the 2020 AACR Virtual Annual Meeting I.
IMRT Betters Patient-Reported Outcomes in Cervical, Endometrial Cancer
May 05, 2020
Article
A reduction in patient-reported symptomatic adverse events (AEs) was observed with intensity-modulated radiotherapy (IMRT) compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AE.